Evidence map›Paper›PMID 40485599›Full record

ArticleEuropean journal of neurology2025

Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort.

Sara Samadzadeh, Frederike Cosima Oertel, Hadi Salih, Ting-Yi Lin, Seyedamirhosein Motamedi, Claudia Chien, Lawrence J Cook, Marco Aurélio Lana-Peixoto, Mariana Andrade Fontenelle, Ho Jin Kim and 54 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

64 authors.

Sara SamadzadehInstitute of Regional Health Research, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0003-3593-1852
Frederike Cosima OertelExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Hadi SalihExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Ting-Yi LinExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Seyedamirhosein MotamediExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Claudia ChienExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Lawrence J CookDepartment of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
Marco Aurélio Lana-PeixotoCIEM MS Research Center, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Mariana Andrade FontenelleCIEM MS Research Center, Medical School, University of Minas Gerais, Belo Horizonte, Brazil.
Ho Jin KimNational Cancer Center Korea, Goyang-si, South Korea.ORCID https://orcid.org/0000-0002-8672-8419
Jae-Won HyunNational Cancer Center Korea, Goyang-si, South Korea.
Su-Kyung JungNational Cancer Center Korea, Goyang-si, South Korea.
Jaqueline PalaceDepartment of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.
Adriana Roca-FernandezDepartment of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.ORCID https://orcid.org/0000-0002-8720-9397
Maria Isabel LeiteDepartment of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.
Srilakshmi M SharmaDepartment of Ophthalmology, Oxford University Hospitals, National Health Service Trust, Oxford, UK.
Fereshteh AshtariKashani MS Center, Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Rahele KafiehDepartment of Engineering, Durham University, Durham, UK.
Alireza DehghaniDepartment of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohsen PouraziziDepartment of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Lekha PanditCenter for Advanced Neurological Research, KS Hegde Medical Academy, Nitte University, Mangalore, India.
Anitha DcunhaCenter for Advanced Neurological Research, KS Hegde Medical Academy, Nitte University, Mangalore, India.
Orhan AktasDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Marius RingelsteinDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Philipp AlbrechtDepartment of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Eugene F MayDepartment of Medicine, Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Caryl TongcoDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Letizia LeocaniUniversity Vita-Salute San Raffaele, Milan, Italy.
Marco PisaNeurological Department and Institute of Experimental Neurology (INSPE) Scientific Institute, Hospital San Raffaele, University Vita-Salute San Raffaele, Milan, Italy.ORCID https://orcid.org/0000-0001-9409-6864
Marta RadaelliDepartment of Nuroscience, Papa Giovanni Paolo XXIII Hospital, Bergamo, Italy.
Bernardo Sánchez-DalmauOphthalmology Department Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.
Elena H Martinez-LapiscinaHospital Clinic of Barcelona-Institut d'Investigacions, Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.ORCID https://orcid.org/0000-0003-4272-0826
Hadas Stiebel-KalishNeuro-Ophthalmology Division, Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Mark A HellmannDepartment of Neurology, Rabin Medical Center, and Faculty of Medicine, Tel Aviv Univeristy, Tel Aviv, Israel.
Itay LotanDepartment of Neurology, Rabin Medical Center, and Faculty of Medicine, Tel Aviv Univeristy, Tel Aviv, Israel.
Sasitorn SirithoSiriraj Neuroimmunology Center, Division of Neurology, Department of Medicine, Siriraj Hospital and Bumrungrad International Hospital, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-2562-697X
Jérôme de SezeNeurology Service, University Hospital of Strasbourg, Strasbourg, France.
Thomas SengerInstitute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
Joachim HavlaInstitute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-4386-1340
Romain MarignierNeurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
Caroline Froment TiliketeDepartment of Neuro-Ophthalmology, Hospices Civils de Lyon, Lyon, France.
Alvaro Cobo-CalvoNeurology Department, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
Denis BichuettiDepartamento de Neurologia e Neurocirurgia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
Ivan Maynart TavaresDepartment of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-2220-7603
Kerstin SoelbergDepartment of Clinical Immunology, Odense University Hospital, Odense, Denmark.
Ayse AltintasNeurology Department, School of Medicine, Koc University, Istanbul, Turkey.
Rengin YildirimDepartment of Ophthalmology, Cerrahpasa Medical Faculty, Istanbul University, Fatih, Turkey.
Uygur TanriverdiNeurology Department Istanbul, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-7770-9179
Anu JacobThe Walton Centre for Neurology and Neurosurgery, NHS Foundation Trust, Liverpool, UK.
Saif HudaThe Walton Centre for Neurology and Neurosurgery, NHS Foundation Trust, Liverpool, UK.
Zoe RimlerDepartment of Neurology, NYU Multiple Sclerosis Comprehensive Care Center, NYU School of Medicine, New York, New York, USA.
Allyson ReidDepartment of Neurology, NYU Multiple Sclerosis Comprehensive Care Center, NYU School of Medicine, New York, New York, USA.
Yang Mao-DraayerDepartment of Neurology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Pablo VillosladaDepartment of Neurology, Hospital del Mar - Pompeu Fabra University, Barcelona, Spain.
Ibis Soto de CastilloDepartment of Neurology, Hospital Clínico de Maracaibo, Maracaibo, Venezuela.
Ari GreenDepartment of Neurology, University of California, San Francisco, San Francisco, California, USA.
Axel PetzoldFaculty of Brain Sciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Michael R YeamanDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Terry J SmithDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, Ann Arbor, Michigan, USA.
Alexander U BrandtExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Hanna G ZimmermannExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Friedemann PaulExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Nasrin AsgariInstitute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Guthy Jackson Charitable Foundation – International Clinical Consortium and CROCTINO Collaborators

Funding

the Guthy-Jackson Charitable Foundationthe Lundbeck Foundation R461-2024-73the University of Southern Denmark, the Slagelse Hospital Research Fund, the Region Zealand Health Sciences Research Fund A11140the University of Southern Denmark, the Slagelse Hospital Research Fund, the Region Zealand Health Sciences Research Fund R41-A1995
6 · The paper itself

Abstract

backgroundComorbidities occur in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and double seronegative NMOSD (DN-NMOSD), potentially contributing to a less favorable disease course.

objectivesTo characterize comorbidities in AQP4-NMOSD, MOGAD, and DN-NMOSD and assess their association with optic neuritis (ON) outcomes by optical coherence tomography (OCT) in AQP4-NMOSD.

methodsFour hundred and forty-two participants from the CROCTINO cohort were evaluated for comorbidities.

resultsIn AQP4-NMOSD patients (n = 360), 43.5% (n = 161) had comorbidities, equally divided between single and multiple. In MOGAD (n = 49), 40.8% had comorbidities, with 75% (n = 15) single and 25% (n = 5) multiple. In DN-NMOSD (n = 33), 36.4% (n = 12) had comorbidities equally split. AQP4-NMOSD patients had more multiple comorbidities (50%, n = 81/161) than MOGAD (25%, n = 5/20, p = 0.03) and more autoimmune disorders (AID) (40.4%, n = 65) than MOGAD (20%, n = 4, p = 0.09) and DN-NMOSD (none, p = 0.004). Cardiovascular comorbidities and related risk factors (CVC/RF) occurred in 34.8% (n = 56) of AQP4-NMOSD, 50% (n = 10) of MOGAD, and 33.3% (n = 4) of DN-NMOSD. Expanded Disability Status Scale was higher in MOGAD (3.0 vs. 2.0, p = 0.006) and DN-NMOSD (5.0 vs. 2.0, p = 0.008) with comorbidities. AQP4-NMOSD patients with CVC/RF had higher ON relapse rates than those with AID (1.06 ± 3.33 vs. 0.49 ± 0.98, p < 0.001). OCT revealed reduced inner nuclear layer thickness in AQP4-NMOSD with comorbidities compared to non-comorbidity (B = -1.52, p = 0.047), more pronounced with CVC/RF (B = -2.96, p = 0.009).

conclusionComorbidities are frequent in AQP4-NMOSD and MOGAD and are associated with ON frequency and disability. These findings highlight the need for proactive comorbidity management to improve patient care.

Indexed as

Aquaporin 4AutoantibodiesMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNeuromyelitis OpticaAdultCohort StudiesComorbidityFemaleHumansMaleMiddle AgedMyelin-Oligodendrocyte GlycoproteinOptic NeuritisTomography, Optical CoherenceYoung AdultAQP4 protein, humanAquaporin 4AutoantibodiesMyelin-Oligodendrocyte Glycoproteinanti‐aquaporin‐4 (AQP4)anti‐myelin oligodendrocyte glycoprotein antibody‐associated diseasecomorbiditydouble‐seronegative NMOSDneuromyelitis optica spectrum disorderoptical coherence tomography

Identifiers

PMID40485599
PMCPMC12146790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.